Xardin 150 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Sharif pharmaceuticals ltd |
Indications
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
- Post operative stress ulcer
- Zollinger-Ellison Syndrome
- Gastroesophageal reflux disease (GERD)
- Gastro-intestinal haemorrhage from stress ulcer in seriously ill patient
- Recurrent haemorrhage in patients with bleeding peptic ulcer
- Before general anesthesia in patient considered to be at risk of acid aspiration particularly obstetric patients
Pharmacology
Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
Dosage & Administration
- Ranitidine Tablet & Syrup:
- Usual dosage is 150 mg twice daily taken in the morning and evening or 300 mg as a single daily dose at night for 4 to 8 weeks
- Reflux oesophagitis: 150 mg twice daily or 300 mg at bedtime for up to 8 weeks
- Episodic dyspepsia: 150 mg twice daily or 300 mg at bedtime for up to 6 weeks
- 150 mg 3 times daily for Zollinger Ellison syndrome
- Children (peptic ulcer): 2-4 mg/kg twice daily, maximum 300 mg daily
- Ranitidine IV injection & IV Infusion:
- Slow intravenous injection of 50 mg, repeated every six to eight hours
- Intermittent intravenous infusion at a rate of 25 mg per hour for two hours
- Intramuscular injection of 50 mg every six to eight hours
- Parenteral administration may be continued until oral feeding commences for prophylaxis of haemorrhage from stress ulceration in seriously ill patients
Interaction
Delayed absorption and increased peak serum concentration with propantheline bromide. Xardin minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam, and propranolol. May alter absorption of pH-dependent drugs. May reduce bioavailability with antacids.
Contraindications
Patients hypersensitive to Ranitidine
Side Effects
Altered bowel habit, dizziness, rash, tiredness, reversible confusional states, headache, decreased blood counts, muscle or joint pain
Pregnancy & Lactation
- Pregnancy: Ranitidine crosses the placenta. No evidence of impaired fertility or harm to the fetus due to Ranitidine. Should only be used during pregnancy if considered essential
- Lactation: Ranitidine is excreted in human breast milk. Caution should be exercised when administered to a nursing mother
Precautions & Warnings
Xardin should be given in reduced dosage to patients with impaired renal and hepatic function
Use in Special Populations
Ulcer healing rates in elderly patients have been found similar to those in younger patients. No difference in the incidence of adverse effects.
Overdose Effects
Xardin is very specific in action and accordingly no particular problems are expected following overdosage with the drug. Symptomatic and supportive therapy should be given as appropriate. If required, the drug may be removed from the plasma by hemodialysis
Therapeutic Class
H2 receptor antagonist
Reconstitution
- Slow IV inj: Xardin 50 mg diluted to a concentration ≤2.5 mg/mL (e.g. total of 20 mL) with NaCl 0.9% inj or dextrose 5% or 10%, lactated Ringer's, Na bicarbonate 5% solution
- Intermittent slow IV infusion: Xardin 50 mg diluted to a concentration ≤0.5 mg/mL (e.g. total of 100 mL) of dextrose 5% inj or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% solution
- Continuous IV infusion: Xardin 150 mg diluted in 250 mL of dextrose 5% inj or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% solution
- Patients with Zollinger-Ellison syndrome or other hypersecretory conditions: Xardin should be diluted to a concentration ≤2.5 mg/mL with dextrose 5% or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% solution
Storage Conditions
Store in a cool and dry place, protect from light